Mumbai, India, June 24, 2019: GlenmarkPharmaceuticals Ltd (Glenmark), a research-led globalintegrated pharmaceutical company, today announced thatits Brazilian subsidiary, Glenmark Farmacêutica Ltdahas entered into an exclusive partnershipagreement with Novartis Biosciences S.A, a subsidiary of NovartisAG, for three respiratory productsindicatedtowards treatment of the symptoms of chronic obstructive pulmonary disease (COPD)in Brazil.This agreement will be effective from July 01, 2019 onwards.
The products involved in the agreement are Seebri® (Glycopyrronium bromide), Onbrize® (Indacaterol) and Ultibro® (combination of Indacaterol and Glycopyrronium), which are indicated for relief of symptoms in adults with COPD.
“We are pleased to partner with Novartis in Brazil. This arrangement with a leading global pharmaceutical company will strengthen our respiratory franchise in Brazil. This partnershipis in line with our vision to expand ourrespiratory product offerings for patients and prescribers in Brazil and further consolidate our position in this segment,” said Glenn Saldanha, Chairman and Managing Director of Glenmark Pharmaceuticals.
Under the terms of the agreement, Novartis remains the holder of the registration of these medicines and willbe responsible to manufacture them with all technical excellence in line with its global commitment to quality, effectiveness and safety. Glenmark will be responsible for promoting, commercializing and distributing of these products in Brazil.